S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Enzolytics Stock Forecast, Price & News

-0.01 (-7.69 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $0.12
50-Day Range
MA: $0.08
52-Week Range
Now: $0.12
Volume28.79 million shs
Average Volume33.92 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Enzolytics Inc., through its subsidiary, Extreme Mobile Coatings, Inc., provides coating solutions in the United States. The company offers franchise opportunities to operate a mobile business that provides painting or coating on various surfaces utilizing specialized proprietary material. It offers products, including anti-microbial protected surface coatings to prevent growth of mold, mildew, and fungus on the surface of the coating, as well as to inhibit growth of microorganisms; marine vessel hull protection coatings that stop barnacles from attaching and does not leach metals into the sea; and general construction coatings for use in various applications, such as architectural, glow in the dark, corrosion protection for iron and steel bridges and beams, epoxy spray for welding projects, blast system for fire restoration, anti-slip, epoxy concrete floors, mold remediation, and blasting and coating guard rails. Enzolytics Inc. was founded in 2007 and is based in Bohemia, New York.


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:ENZC



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.01 (-7.69 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENZC News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Enzolytics (OTCMKTS:ENZC) Frequently Asked Questions

What stocks does MarketBeat like better than Enzolytics?

Wall Street analysts have given Enzolytics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enzolytics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Enzolytics?

Enzolytics saw a decrease in short interest in December. As of December 31st, there was short interest totaling 57,600 shares, a decrease of 98.1% from the December 15th total of 2,968,400 shares. Based on an average daily trading volume, of 145,129,900 shares, the short-interest ratio is currently 0.0 days.
View Enzolytics' Short Interest

Who are some of Enzolytics' key competitors?

Who are Enzolytics' key executives?

Enzolytics' management team includes the following people:
  • Mr. Charles S. Cotropia, CEO, Pres & Director
  • Mr. Rodney Barrington, Chief Operating Officer
  • Mr. Harry H. Zhabilov Jr., CSO & Director (Age 54)
  • Dr. Joseph P. Cotropia M.D., Chief Medical Officer

What is Enzolytics' stock symbol?

Enzolytics trades on the OTCMKTS under the ticker symbol "ENZC."

How do I buy shares of Enzolytics?

Shares of ENZC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzolytics' stock price today?

One share of ENZC stock can currently be purchased for approximately $0.12.

What is Enzolytics' official website?

The official website for Enzolytics is enzolytics.com.

How can I contact Enzolytics?

The company can be reached via phone at 631-256-5149.

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.